{"Title": "Long-acting cabotegravir for prevention: hope versus reality", "Year": 2017, "Source": "Lancet HIV", "Volume": "4", "Issue": 8, "Art.No": null, "PageStart": null, "PageEnd": null, "CitedBy": 3, "DOI": "10.1016/S2352-3018(17)30074-7", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85019593106&origin=inward", "Abstract": null, "AuthorKeywords": null, "IndexKeywords": ["Anti-HIV Agents", "HIV Infections", "Humans", "Pyridones"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85019593106", "SubjectAreas": [["Epidemiology", "MEDI", "2713"], ["Immunology", "IMMU", "2403"], ["Infectious Diseases", "MEDI", "2725"], ["Virology", "IMMU", "2406"]], "AuthorData": {"23482010600": {"Name": "McCormack S.", "AuthorID": "23482010600", "AffiliationID": "60002484", "AffiliationName": "Chelsea and Westminster Hospital"}, "7004703572": {"Name": "Boffito M.", "AuthorID": "7004703572", "AffiliationID": "60002484", "AffiliationName": "Chelsea and Westminster Hospital"}}}